Jessica Fye
Stock Analyst at JP Morgan
(4.47)
# 282
Out of 5,114 analysts
219
Total ratings
59.85%
Success rate
15.94%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $16.85 | +54.30% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $31.96 | -21.78% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $12.84 | +79.13% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $166.99 | +19.17% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $67.35 | -3.49% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $33.80 | -26.04% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $92.50 | +29.73% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $400.23 | +18.18% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $21.92 | +246.72% | 4 | Oct 9, 2025 | |
| INCY Incyte | Maintains: Neutral | $73 → $89 | $102.69 | -13.33% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $61.15 | +94.60% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $199.99 | +32.01% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $456.20 | +16.18% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $316.05 | +21.82% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $79.57 | +0.54% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $48.01 | +8.31% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $77.74 | -0.95% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $28.45 | +23.02% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $174.84 | -22.79% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $517.13 | -36.19% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.41 | +75.44% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $36.01 | +38.85% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $30.42 | -1.38% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $46.84 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $12.42 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $3.93 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $13.80 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.93 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.17 | +498.29% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $29.03 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.66 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.39 | - | 1 | Feb 8, 2018 |
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $16.85
Upside: +54.30%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $31.96
Upside: -21.78%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $12.84
Upside: +79.13%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $166.99
Upside: +19.17%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $67.35
Upside: -3.49%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $33.80
Upside: -26.04%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $92.50
Upside: +29.73%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $400.23
Upside: +18.18%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $21.92
Upside: +246.72%
Incyte
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $102.69
Upside: -13.33%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $61.15
Upside: +94.60%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $199.99
Upside: +32.01%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $456.20
Upside: +16.18%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $316.05
Upside: +21.82%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $79.57
Upside: +0.54%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $48.01
Upside: +8.31%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $77.74
Upside: -0.95%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $28.45
Upside: +23.02%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $174.84
Upside: -22.79%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $517.13
Upside: -36.19%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.41
Upside: +75.44%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $36.01
Upside: +38.85%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $30.42
Upside: -1.38%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $46.84
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $12.42
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $3.93
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $13.80
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.93
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.17
Upside: +498.29%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $29.03
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.66
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $15.39
Upside: -